(Q46650430)

English

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder

scientific article published in September 2005

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

author name string

Denise B Serra

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

Melton B Affrime

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

Martin P Bedigian

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

Gerard Greig

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

Slavica Milosavljev

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

Andrej Skerjanec

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

Yibin Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

publication date

1 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

45

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

1038-1047

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Muscarinic antagonists in development for disorders of smooth muscle function

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Drug-induced prolongation of the QT interval

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

What Clinicians Should Know About the QT Interval

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

The impact of drug-induced QT interval prolongation on drug discovery and development

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

The Duration of Systole in an Electrocardiogram in Normal Humans and in Patients with Heart Disease*

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Rate-corrected QT interval: techniques and limitations

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Evaluation of vardenafil and sildenafil on cardiac repolarization

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Torsades de pointes complicating treatment with terodiline

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279010

21 January 2018

Identifiers

10.1177/0091270005279010

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100298

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46650430&oldid=2124294042"